Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication

被引:104
作者
Olesen, OV [1 ]
Linnet, K [1 ]
机构
[1] Aarhus Univ Hosp, Hosp Psychiat, Dept Biol Psychiat, Inst Basic Psychiat Res, DK-8240 Risskov, Denmark
关键词
olanzapine; serum concentration; psychiatric patients; comedication;
D O I
10.1097/00007691-199902000-00013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We recorded steady state serum concentrations of olanzapine in 56 psychiatric patients under routine conditions. Twenty-two patients (39%) underwent monotherapy; the rest received additional psychotropic drugs. Doses were given once daily in the evening, and serum olanzapine levels were measured 12 hours later. For the whole group, the concentration-to-dose ratio (C/D) varied 26-fold, with a median value of 4.8 (nmol/L)/(mg/24 hours), but 80% of the patients had C/D values within the range 2 to 10 (nmol/L)/ (mg/24 hours). All but three patients received standard doses (5-20 mg/24 hours), of whom 80% had serum concentrations of olanzapine within the range 22 to 146 nmol/L. Patients comedicated with potential inhibitors of CYP2D6 and other drugs displayed a median C/D approximately 40% higher than the group undergoing monotherapy. Patients comedicated with carbamazepine had a median C/D 36% lower than that of the monotherapy group. Therefore, the serum concentration range (12-hour values) of 25 to 150 nmol/L can be expected for patients receiving a standard daily dose.
引用
收藏
页码:87 / 90
页数:4
相关论文
共 18 条
[1]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[2]  
Casey DE, 1997, J CLIN PSYCHIAT, V58, P55
[3]  
Dellva MA, 1997, PSYCHIATR SERV, V48, P1571
[4]  
Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
[5]   DRUG INTERACTION - INHIBITORY EFFECT OF NEUROLEPTICS ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN [J].
GRAM, LF ;
OVERO, KF .
BRITISH MEDICAL JOURNAL, 1972, 1 (5798) :463-&
[6]   THE USE OF THERAPEUTIC DRUG-MONITORING DATA TO DOCUMENT KINETIC DRUG-INTERACTIONS - AN EXAMPLE WITH AMITRIPTYLINE AND NORTRIPTYLINE [J].
JERLING, M ;
BERTILSSON, L ;
SJOQVIST, F .
THERAPEUTIC DRUG MONITORING, 1994, 16 (01) :1-12
[7]   The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol [J].
Jerling, M ;
Dahl, ML ;
AbergWistedt, A ;
Liljenberg, B ;
Landell, NE ;
Bertilsson, L ;
Sjoqvist, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) :423-428
[8]   FLUVOXAMINE INHIBITION AND CARBAMAZEPINE INDUCTION OF THE METABOLISM OF CLOZAPINE - EVIDENCE FROM A THERAPEUTIC DRUG-MONITORING SERVICE [J].
JERLING, M ;
LINDSTROM, L ;
BONDESSON, U ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1994, 16 (04) :368-374
[9]  
Kassahun K, 1997, DRUG METAB DISPOS, V25, P81
[10]   COMPARISON OF THE KINETIC INTERACTIONS OF THE NEUROLEPTICS PERPHENAZINE AND ZUCLOPENTHIXOL WITH TRICYCLIC ANTIDEPRESSIVES [J].
LINNET, K .
THERAPEUTIC DRUG MONITORING, 1995, 17 (03) :308-311